Overview

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Status:
Recruiting

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Gemcitabine
Paclitaxel
Pembrolizumab